154 related articles for article (PubMed ID: 37138324)
1. The potential crosstalk between tumor and plasma cells and its association with clinical outcome and immunotherapy response in bladder cancer.
Long F; Wang W; Li S; Wang B; Hu X; Wang J; Xu Y; Liu M; Zhou J; Si H; Xi X; Meng XY; Yuan C; Wang F
J Transl Med; 2023 May; 21(1):298. PubMed ID: 37138324
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
Zhao S; Wang L; Ding W; Ye B; Cheng C; Shao J; Liu J; Zhou H
Front Endocrinol (Lausanne); 2023; 14():1180404. PubMed ID: 37152941
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
6. Derivation and Comprehensive Analysis of Aging Patterns in Patients with Bladder Cancer.
Wang B; Tong F; Zhai C; Wang L; Liu Y; Wang J
Dis Markers; 2021; 2021():3385058. PubMed ID: 34721733
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the immune cell infiltration landscape in bladder cancer to aid immunotherapy.
Shi S; Ma T; Xi Y
Arch Biochem Biophys; 2021 Sep; 708():108950. PubMed ID: 34118215
[TBL] [Abstract][Full Text] [Related]
8. A prognostic risk prediction model based on ferroptosis-related long non-coding RNAs in bladder cancer: A bulk RNA-seq research and scRNA-seq validation.
Xiang X; Guo Y; Chen Z; Zhang F; Huang J; Qin Y
Medicine (Baltimore); 2022 Dec; 101(51):e32558. PubMed ID: 36595859
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk between Mesenchymal Stem Cells and Cancer Stem Cells Reveals a Novel Stemness-Related Signature to Predict Prognosis and Immunotherapy Responses for Bladder Cancer Patients.
Ma L; Chen H; Yang W; Ji Z
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902193
[TBL] [Abstract][Full Text] [Related]
10. High expression of COL6A1 predicts poor prognosis and response to immunotherapy in bladder cancer.
Zhang X; Liu J; Yang X; Jiao W; Shen C; Zhao X; Wang Y
Cell Cycle; 2023 Mar; 22(5):610-618. PubMed ID: 36474424
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Epithelial-Mesenchymal Transition Identifies a Gene Signature for Predicting Clinical Outcomes and Therapeutic Responses in Bladder Cancer.
Wang Y; Zhang H; Hu X
Dis Markers; 2022; 2022():9593039. PubMed ID: 36457546
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer.
Chen J; Liao Y; Li R; Luo M; Wu G; Tan R; Xiao Z
Technol Cancer Res Treat; 2022; 21():15330338221090093. PubMed ID: 35509211
[No Abstract] [Full Text] [Related]
13. Comprehensive analyses of a tumor-infiltrating lymphocytes-related gene signature regarding the prognosis and immunologic features for immunotherapy in bladder cancer on the basis of WGCNA.
He Z; Gu J; Luan T; Li H; Li C; Chen Z; Luo E; Wang J; Huang Y; Ding M
Front Immunol; 2022; 13():973974. PubMed ID: 36211333
[TBL] [Abstract][Full Text] [Related]
14. Delineation of colorectal cancer ligand-receptor interactions and their roles in the tumor microenvironment and prognosis.
Lin H; Xia L; Lian J; Chen Y; Zhang Y; Zhuang Z; Cai H; You J; Guan G
J Transl Med; 2021 Dec; 19(1):497. PubMed ID: 34876143
[TBL] [Abstract][Full Text] [Related]
15. Intercellular Molecular Crosstalk Networks within Invasive and Immunosuppressive Tumor Microenvironment Subtypes Associated with Clinical Outcomes in Four Cancer Types.
Wei J; Yu W; Wu L; Chen Z; Huang G; Hu M; Du H
Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002057
[TBL] [Abstract][Full Text] [Related]
16. Multi-Omics Characterization of Tumor Microenvironment Heterogeneity and Immunotherapy Resistance Through Cell States-Based Subtyping in Bladder Cancer.
Hu R; Tao T; Yu L; Ding Q; Zhu G; Peng G; Zheng S; Yang L; Wu S
Front Cell Dev Biol; 2021; 9():809588. PubMed ID: 35223867
[TBL] [Abstract][Full Text] [Related]
17. Identification of cuproptosis-related long noncoding RNA signature for predicting prognosis and immunotherapy response in bladder cancer.
Huang G; Huang Y; Zhang C; Jiang Y; Ye Z; He C; Yu F; Chen Z; Xi X
Sci Rep; 2022 Dec; 12(1):21386. PubMed ID: 36496537
[TBL] [Abstract][Full Text] [Related]
18. iATMEcell: identification of abnormal tumor microenvironment cells to predict the clinical outcomes in cancer based on cell-cell crosstalk network.
Sheng Y; Wu J; Li X; Qiu J; Li J; Ge Q; Cheng L; Han J
Brief Bioinform; 2023 Mar; 24(2):. PubMed ID: 36864591
[TBL] [Abstract][Full Text] [Related]
19. Single-Cell Transcriptomic Analysis Reveals the Crosstalk Propensity Between the Tumor Intermediate State and the CD8+ T Exhausted State to be Associated with Clinical Benefits in Melanoma.
Zhu J; Yan M; Yan H; Xu L; Jiang Z; Liao G; Zhou Y; Liu W; Liang X; Li X; Xiao Y; Zhang Y
Front Immunol; 2022; 13():766852. PubMed ID: 35903095
[TBL] [Abstract][Full Text] [Related]
20. A hypoxia related long non-coding RNA signature could accurately predict survival outcomes in patients with bladder cancer.
Zhang F; Wang X; Hu H; Yang Y; Wang J; Tang Y; Li D; Bai Y; Han P
Bioengineered; 2021 Dec; 12(1):3802-3823. PubMed ID: 34281486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
